Compliance Status
Not Halal
Screened on Oct 14, 2026 · AAOIFI Standard 21
Non-Compliant
Is HUTCHMED (China) Limited (HCM) halal? Not Halal. Based on AAOIFI screening, HUTCHMED (China) Limited passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
Quote this verdict
HalalScreener rates HUTCHMED (China) Limited (HCM) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Oct 14, 2026. Source: https://halalscreener.app/en/stock/HCM
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
Most scholars advise not holding HCM
It does not pass AAOIFI Shariah screening.
See halal alternatives from the same sector further down this page
HCM: Is HUTCHMED (China) Limited Halal?
HUTCHMED (China) Limited
$14.05
Market Cap: 2.5B
Get an email if HCM's halal status changes
We re-screen HUTCHMED (China) Limited daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic
Why this does not pass
- Interest-bearing deposits are over the 30% limit.
- Income from prohibited sources is over the 5% limit.
Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.
Shariah Compliance Status
See which ratio caused the failure.
See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.
AI Compliance Insight
PROInstitutional-grade Shariah analysis
See why HCM is rated Not Halal with institutional-grade analysis
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
Compliance History
Not Halal, unchanged since May 2026.
No status changes recorded since we began tracking.
Tracked since May 2026. Updates automatically on each re-screen.
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Know the day HCM's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is HUTCHMED (China) Limited (HCM) halal to invest in?
Why did HUTCHMED (China) Limited get a F compliance rating?
What could change HUTCHMED (China) Limited's Shariah verdict?
How often is HUTCHMED (China) Limited re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.